PharmaCog is short for “Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in early clinical development”. It is a partnership of 32 academic and industry actors from 7 countries, co-ordinated by GlaxoSmithKline R&D and the Université de la Méditerranée, started its activities on January 1, 2010 thanks to significant funding (EUR 20.2 million) from the Innovative Medicines Initiative. Its launch marks the start of the most ambitious European project for tackling bottlenecks in Alzheimer's disease research and drug discovery.
PharmaCog will provide the tools needed to define more precisely the potential of a drug candidate, reduce the development time of new medicines and thus accelerate the approvals of promising new medicines.
Last Updated: jeudi 13 novembre 2014